Wall Street Bullish on Soleno Therapeutics Ahead of Key FDA Decision

While shares of Soleno Therapeutics saw minimal movement in Friday’s trading session, closing with a slight decline, this surface-level calm belies a significant surge of confidence emanating from Wall Street. Multiple market analysts are highlighting substantial potential in the biotechnology firm, pointing to a major upcoming regulatory catalyst.

Regulatory Milestone Drives Focus

The company’s primary focus is developing therapies for rare diseases. Its most closely watched program is the drug candidate DCCR for Prader-Willi syndrome, a condition that currently lacks any approved pharmacological treatments.

The U.S. Food and Drug Administration (FDA) has set a target action date of March 27, 2025, for its decision on the drug’s approval. This date represents a postponement from the original late December 2024 deadline. The delay occurred after the agency classified additional data submitted by Soleno as a “major amendment,” requiring more time for review. Notably, the FDA has not raised any concerns regarding the drug’s safety, efficacy, or manufacturing processes to date. The investment thesis for the stock is widely considered to hinge on the outcome of this pivotal regulatory review.

Overwhelming Analyst Consensus

Recent data from MarketBeat indicates a strong consensus among covering firms. Soleno Therapeutics receives an average rating of “Buy” from the fifteen brokerages that provide coverage. Their collective average price target stands at $111.46, suggesting an upside potential of more than 115% from the last closing price.

Should investors sell immediately? Or is it worth buying Soleno Therapeut.?

This optimistic stance is shared by several prominent institutions. In November, Wells Fargo reaffirmed an “Overweight” rating with a $106 price target. Wolfe Research initiated coverage with an “Outperform” recommendation and a $75 target. Furthermore, Goldman Sachs issued a “Buy” rating back in October, accompanied by an ambitious $125 price target.

Institutional Investors Increase Stakes

Mirroring analyst sentiment, major institutional investors have been actively building their positions, a move typically interpreted as a sign of long-term confidence in the company’s strategy.

Investment manager Rhumbline Advisers increased its stake by 62% during the second quarter. Other notable institutions, including Wellington Management, Invesco, and Price T Rowe Associates, significantly expanded their holdings during the first and third quarters of the year. This accumulation by sophisticated investors underscores the building expectations for a favorable regulatory outcome in March.